Patients in the group had various GI cancers including:
• Colon cancer: 48 percent
• Rectal cancer: 42.8 percent
• Esophageal cancer: 10.2 percent
The subgroup of patients who took aspirin had a five-year survival rate of 75 percent, while the patients who did not take aspirin had a five-year survival rate of 40 percent.
More articles on gastroenterology:
FDA approves new CRC drug
Beyond patient care: The biggest challenges in GI
4 GI physicians in the news – Sept. 25, 2015
